期刊
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 56, 期 2, 页码 209-223出版社
WILEY
DOI: 10.1111/apt.17046
关键词
-
资金
- Agence Nationale de la Recherche [ANR-18-CE14-0006-01]
- RHU QUID-NASH [ANR-18-IDEX-00]
- Instituto de Salud Carlos III [FIS PI20/00220]
- Agence Nationale de la Recherche (ANR) [ANR-18-CE14-0006] Funding Source: Agence Nationale de la Recherche (ANR)
This review summarizes and discusses the pathobiological role of PPARs in cardiovascular diseases, with a special focus on their impact and therapeutic potential in NAFLD and NASH. The importance of evaluating cardiovascular disease in the context of NASH trials is emphasized.
Background Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors known to regulate glucose and fatty acid metabolism, inflammation, endothelial function and fibrosis. PPAR isoforms have been extensively studied in metabolic diseases, including type 2 diabetes and cardiovascular diseases. Recent data extend the key role of PPARs to liver diseases coursing with vascular dysfunction, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Aim This review summarises and discusses the pathobiological role of PPARs in cardiovascular diseases with a special focus on their impact and therapeutic potential in NAFLD and NASH. Results and Conclusions PPARs may be attractive for the treatment of NASH due to their liver-specific effects but also because of their efficacy in improving cardiovascular outcomes, which may later impact liver disease. Assessment of cardiovascular disease in the context of NASH trials is, therefore, of the utmost importance, both from a safety and efficacy perspective.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据